Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion type Assertion NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_head.
- NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion description "[To determine the maximum tolerated dose (MTD) of the oral mTOR inhibitor everolimus in advanced HCC patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_provenance.
- NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion evidence source_evidence_literature NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_provenance.
- NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion SIO_000772 23134470 NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_provenance.
- NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion wasDerivedFrom befree-2016 NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_provenance.
- NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_assertion wasGeneratedBy ECO_0000203 NP1026659.RAfGOb_UIzfNz2Eg0kWg1Bk7PsAwrSeviJllv8Bq0yVtA130_provenance.